ES2627099T3 - Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR - Google Patents
Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR Download PDFInfo
- Publication number
- ES2627099T3 ES2627099T3 ES13827913T ES13827913T ES2627099T3 ES 2627099 T3 ES2627099 T3 ES 2627099T3 ES 13827913 T ES13827913 T ES 13827913T ES 13827913 T ES13827913 T ES 13827913T ES 2627099 T3 ES2627099 T3 ES 2627099T3
- Authority
- ES
- Spain
- Prior art keywords
- diseases related
- diseases
- alkyl
- treatment
- mtor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/62—Carboxylic acid nitriles containing cyano groups and oxygen atoms being part of oxyimino groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
Abstract
Un compuesto de la Fórmula (I): o una sal aceptable farmacéuticamente, o solvato de este, para usar en el tratamiento de una o más enfermedades relacionadas con la vía de mTOR, en donde la una, o más enfermedades relacionadas con la vía de mTOR se seleccionan de enfermedades neurodegenerativas, enfermedades relacionadas con la edad, enfermedades relacionadas con el rechazo de trasplante, enfermedades inflamatorias crónicas, enfermedades relacionadas con el almacenamiento de glucógeno, lupus sistémico, enfermedades relacionadas con la inflamación y la activación inmune, anemia, leucopenia, trombocitopenia, enfermedades relacionadas con el recubrimiento de endoprótesis, insuficiencia renal, obesidad, diabetes/resistencia a la insulina, enfermedades relacionadas con el hígado graso no alcohólico, riñón poliquístico y fibrosis y en donde, R1 es -CN; R2 y R3 y R5 cada uno se selecciona independientemente de H, alquilo, halógeno, -CF3 o -CN; R4 y R6 cada uno se selecciona independientemente de H, alquilo, halógeno, alcoxi, -CF3, -OCF3, -SO2CF3, - SOCF3 o -SCF3; X es un heteroátomo, N(alquil) o NH; y n es de 1 a 20.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012903365A AU2012903365A0 (en) | 2012-08-06 | Compounds for the treatment of mTOR pathway related diseases | |
PCT/AU2013/000859 WO2014022879A1 (en) | 2012-08-06 | 2013-08-05 | Compounds for the treatment of mtor pathway related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2627099T3 true ES2627099T3 (es) | 2017-07-26 |
Family
ID=50067298
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13827913T Active ES2627099T3 (es) | 2012-08-06 | 2013-08-05 | Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR |
ES17162895T Active ES2757598T3 (es) | 2012-08-06 | 2013-08-05 | Compuestos para el tratamiento de las enfermedades relacionadas con la vía mTOR |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES17162895T Active ES2757598T3 (es) | 2012-08-06 | 2013-08-05 | Compuestos para el tratamiento de las enfermedades relacionadas con la vía mTOR |
Country Status (13)
Country | Link |
---|---|
US (2) | US9790176B2 (es) |
EP (2) | EP3202397B1 (es) |
JP (2) | JP6441219B2 (es) |
KR (1) | KR102124392B1 (es) |
CN (2) | CN105496999A (es) |
AU (2) | AU2013302209B2 (es) |
CA (1) | CA2881325C (es) |
ES (2) | ES2627099T3 (es) |
HK (1) | HK1205502A1 (es) |
NZ (2) | NZ631523A (es) |
PL (1) | PL2880014T3 (es) |
WO (1) | WO2014022879A1 (es) |
ZA (1) | ZA201501390B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2627099T3 (es) | 2012-08-06 | 2017-07-26 | Pitney Pharmaceuticals Pty Limited | Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR |
AU2014344789B2 (en) * | 2013-11-01 | 2019-10-03 | Pitney Pharmaceuticals Pty Limited | Pharmaceutical combinations for the treatment of cancer |
US10258639B2 (en) * | 2014-05-06 | 2019-04-16 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy |
RS64114B1 (sr) | 2015-10-23 | 2023-04-28 | Navitor Pharm Inc | Modulatori interakcije sestrin-gator2 i nјihova upotreba |
WO2018200625A1 (en) | 2017-04-26 | 2018-11-01 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
JP2022500384A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス, インコーポレイテッド | 組み合わせ療法 |
WO2020086816A1 (en) * | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
WO2021087432A1 (en) * | 2019-11-01 | 2021-05-06 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mtorc1 modulator |
KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
CN113577086B (zh) * | 2020-04-30 | 2023-05-02 | 沈阳福洋医药科技有限公司 | 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用 |
EP4149454A1 (en) * | 2020-05-11 | 2023-03-22 | Pitney Pharmaceuticals Pty Limited | Use of aminoacetonitrile compounds for the treatment of infection and disease |
CN115304600B (zh) * | 2022-09-29 | 2023-01-13 | 北京鑫开元医药科技有限公司 | mTOR抑制剂、制备方法及用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6239077B1 (en) * | 1998-05-01 | 2001-05-29 | Nihon Nohyaku Co., Ltd. | Aminoacetonitrile derivative agricultural and horticultural insecticide containing the same and use thereof |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
TWI292712B (en) * | 2000-12-20 | 2008-01-21 | Novartis Ag | Aminoacetonitrile compounds for use in the control of endoparasites |
DK1812385T3 (da) * | 2004-11-09 | 2012-10-15 | Novartis Ag | Fremgangsmåde til fremstilling af enantiomere af amidoacetonitrilforbindelser ud fra deres racemater |
US20090286838A1 (en) * | 2004-12-06 | 2009-11-19 | Newsouth Innovations Pty Limited | Treatment for cancer |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
CN105534969B (zh) * | 2012-03-23 | 2019-04-05 | 皮特尼制药股份有限公司 | 用于癌症治疗的激酶抑制剂 |
ES2627099T3 (es) | 2012-08-06 | 2017-07-26 | Pitney Pharmaceuticals Pty Limited | Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR |
AU2014344789B2 (en) * | 2013-11-01 | 2019-10-03 | Pitney Pharmaceuticals Pty Limited | Pharmaceutical combinations for the treatment of cancer |
-
2013
- 2013-08-05 ES ES13827913T patent/ES2627099T3/es active Active
- 2013-08-05 CA CA2881325A patent/CA2881325C/en active Active
- 2013-08-05 AU AU2013302209A patent/AU2013302209B2/en active Active
- 2013-08-05 PL PL13827913T patent/PL2880014T3/pl unknown
- 2013-08-05 NZ NZ631523A patent/NZ631523A/en unknown
- 2013-08-05 ES ES17162895T patent/ES2757598T3/es active Active
- 2013-08-05 KR KR1020157003924A patent/KR102124392B1/ko active IP Right Grant
- 2013-08-05 NZ NZ729555A patent/NZ729555A/en not_active IP Right Cessation
- 2013-08-05 JP JP2015525692A patent/JP6441219B2/ja active Active
- 2013-08-05 WO PCT/AU2013/000859 patent/WO2014022879A1/en active Application Filing
- 2013-08-05 CN CN201510883323.4A patent/CN105496999A/zh active Pending
- 2013-08-05 CN CN201380051602.3A patent/CN104837812B/zh active Active
- 2013-08-05 US US14/420,081 patent/US9790176B2/en active Active
- 2013-08-05 EP EP17162895.1A patent/EP3202397B1/en active Active
- 2013-08-05 EP EP13827913.8A patent/EP2880014B1/en active Active
-
2015
- 2015-03-02 ZA ZA2015/01390A patent/ZA201501390B/en unknown
- 2015-06-25 HK HK15106070.3A patent/HK1205502A1/xx unknown
-
2016
- 2016-09-28 AU AU2016234924A patent/AU2016234924B2/en not_active Ceased
-
2017
- 2017-06-05 US US15/613,635 patent/US10053422B2/en active Active
-
2018
- 2018-01-12 JP JP2018003249A patent/JP6509386B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20150166477A1 (en) | 2015-06-18 |
US9790176B2 (en) | 2017-10-17 |
US20170369435A1 (en) | 2017-12-28 |
CA2881325C (en) | 2020-09-29 |
AU2013302209B2 (en) | 2016-09-29 |
CN104837812B (zh) | 2017-09-26 |
PL2880014T3 (pl) | 2017-10-31 |
CA2881325A1 (en) | 2014-02-13 |
WO2014022879A1 (en) | 2014-02-13 |
CN105496999A (zh) | 2016-04-20 |
JP6441219B2 (ja) | 2018-12-19 |
JP2018062526A (ja) | 2018-04-19 |
ES2757598T3 (es) | 2020-04-29 |
EP2880014A1 (en) | 2015-06-10 |
EP3202397B1 (en) | 2019-09-25 |
JP6509386B2 (ja) | 2019-05-08 |
AU2016234924B2 (en) | 2017-04-13 |
KR20150081422A (ko) | 2015-07-14 |
JP2015524446A (ja) | 2015-08-24 |
NZ631523A (en) | 2017-03-31 |
EP3202397A1 (en) | 2017-08-09 |
CN104837812A (zh) | 2015-08-12 |
AU2013302209A1 (en) | 2015-02-19 |
EP2880014A4 (en) | 2015-12-30 |
HK1205502A1 (en) | 2015-12-18 |
NZ729555A (en) | 2017-08-25 |
US10053422B2 (en) | 2018-08-21 |
AU2016234924A1 (en) | 2016-10-20 |
KR102124392B1 (ko) | 2020-06-19 |
EP2880014B1 (en) | 2017-05-17 |
ZA201501390B (en) | 2017-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2627099T3 (es) | Compuestos para el tratamiento de enfermedades relacionadas con la vía de mTOR | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR087870A1 (es) | Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina | |
PE20170939A1 (es) | Pirimidinonas como inhibidores del factor xia | |
UY33842A (es) | ?pesticidas mesoiónicos?. | |
MX2022008434A (es) | Herbicidas de piridazinona. | |
AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
PH12014502866A1 (en) | Fungicidal heterocyclic carboxamides | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
JP2010504286A5 (es) | ||
JP2013542218A5 (es) | ||
RS54730B1 (sr) | Inhibitori beta sekretaze | |
WO2013076315A3 (en) | Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides | |
AR087909A1 (es) | Composiciones farmaceuticas | |
MX2015012629A (es) | Compuestos de imidazo piridina. | |
RS54183B1 (en) | PIRAZOLE DERIVATIVES | |
EA201690515A1 (ru) | Производные диазокарбазола в качестве пэт-лигандов белка tau | |
AR094272A1 (es) | Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo | |
JP2018526419A5 (es) | ||
MX2015014406A (es) | Carboxamidas fungicidas. | |
AR080703A1 (es) | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. | |
AR101132A1 (es) | Derivados de pirazina agonistas del gpr40 para el tratamiento de la diabetes tipo ii | |
AR093057A1 (es) | Inhibidores de la syk |